83506 Federal Register / Vol. 89, No. 200 / Wednesday, October 16, 2024 / Notices 

America’s diverse population. ODPHP 

strives to be responsive to the needs of 

America’s diverse audiences while 

simultaneously serving all Americans 

across a range of channels, from print to 

new communication technologies. To 

carry out prevention information efforts, 

ODPHP is committed to conducting 

formative and usability research to 

provide guidance on the development 

and implementation of their 

communication and education efforts. 

The information collected will be used 

to improve communication, products, 

and services that support key office 

activities including: Healthy People, 

Dietary Guidelines for Americans, Food 

Is Medicine, Physical Activity 

Guidelines for Americans, 

MyHealthfinder, the Move Your Way®

Campaign, the President’s Council on 

Sports, Fitness & Nutrition, health 

literacy and healthy aging. ODPHP 

communicates through its website 

(www.health.gov) and through other 

channels including social media, print 

materials, interactive training modules, 

and reports. This request builds on 

previous formative research approaches 

to place more emphasis on Web-based 

data collection to allow greater 

geographical diversity among 

respondents, to decrease respondent 

burden, and to save government costs. 

Data collection will be qualitative and 

quantitative and may include in-depth 

interviews, focus groups, web-based 

surveys, omnibus surveys, card sorting, 

and various forms of usability testing of 

materials and interactive tools to assess 

the public’s understanding of disease 

prevention and health promotion 

content, responses to prototype 

materials, and barriers to effective use. 

The program is requesting a 3-year 

extension of its clearance. 

ANNUALIZED BURDEN HOUR TABLE

Forms 

(if necessary) 

Number of 

respondents 

Number of 

responses per 

respondents 

Average 

burden per 

response 

Total burden 

hours 

In-depth interviews—Screener ............................................................................ 500 1 10/60 83 

In-depth interviews—Instrument .......................................................................... 167 1 1.00 167 

Focus groups—Screener ..................................................................................... 975 1 10/60 162.5 

Focus groups—Instrument .................................................................................. 325 1 1.50 487.5 

Intercept interviews .............................................................................................. 1750 1 5/60 146 

Cognitive testing of instruments—Screener ........................................................ 50 1 10/60 8 

Cognitive testing of instruments—Cognitive test ................................................. 17 1 2.00 34 

Web-based surveys—Screener ........................................................................... 10,000 1 5/60 833 

Web-based surveys—Survey .............................................................................. 3,333 1 15/60 833 

Omnibus surveys ................................................................................................. 700 1 10/60 117

Gatekeeper reviews ............................................................................................. 109 1 30/60 54 

Card sorting—Screener ....................................................................................... 200 1 10/60 33 

Card sorting—Card sort ....................................................................................... 67 1 1.00 67 

Usability and prototype testing of materials (print and web)—Screener ............. 600 1 10/60 100 

Usability and prototype testing of materials (print and web)—usability tests ..... 208 1 1.00 208 

Total .............................................................................................................. ...................... .......................... .................... 3,333 

Sherrette A. Funn, 

Paperwork Reduction Act Reports Clearance 

Officer, Office of the Secretary. 

[FR Doc. 2024–23795 Filed 10–15–24; 8:45 am] 

BILLING CODE 4150–32–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Basic 

Biology of Blood, Heart, and Vasculature. 

Date: November 7, 2024. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Aisha Lanette Walker, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, 6701 Rockledge Drive, 

Bethesda, MD 20892, 301–594–3527, 

aisha.walker@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Oncology. 

Date: November 7–8, 2024. 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Reigh-Yi Lin, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Rm. 4152, 

MSC 7846, Bethesda, MD 20892, (301) 827– 

6009, lin.reigh-yi@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; S10 

Instrumentation: Flow Cytometry. 

Date: November 7, 2024. 

Time: 11:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Jessica Smith, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 402–3717, jessica.smith6@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Topics in Pathogenic Eukaryotes. 

Date: November 7, 2024. 

Time: 2:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 200 / Wednesday, October 16, 2024 / Notices 83507 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Velasco Cimica, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 594–1760, velasco.cimica@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Musculoskeletal Sciences in 

Diagnostics, Devices, and Rehabilitation. 

Date: November 12–13, 2024. 

Time: 8:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: Melrose Hotel, 2430 Pennsylvania 

Ave. NW, Washington, DC 20037. 

Meeting Format: In Person. 

Contact Person: Amber Taylor Collins, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 827–5245, amber.collins@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Applied Immunology and Vaccine 

Development. 

Date: November 12–13, 2024. 

Time: 8:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: Residence Inn Bethesda, 7335 

Wisconsin Avenue, Bethesda, MD 20814. 

Meeting Format: In Person. 

Contact Person: Dayadevi Jirage, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4422, 

Bethesda, MD 20892, (301) 867–5309, 

jiragedb@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Small 

Business: Cancer Diagnosis and Treatments 

(CDT). 

Date: November 12–13, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Victor A. Panchenko, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 802B2, 

Bethesda, MD 20892, (301) 867–5309, 

victor.panchenko@nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis; Panel 

Fellowships: Vascular and Hematological 

Systems, Surgical Sciences, Biomedical 

Imaging, and Bioengineering. 

Date: November 12–13, 2024. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Courtney Elaine Watkins, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 496–3093, courtney.watkins2@

nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Infectious Disease and 

Immunology A. 

Date: November 12–13, 2024. 

Time: 9:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: Maria Chiara G. MonacoKushner, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Dr., 

Bethesda, MD 20892, (301) 555–1212, 

monaco@csr.nih.gov. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; 

Fellowships: Behavioral Neuroscience. 

Date: November 12–13, 2024. 

Time: 10:00 a.m. to 8:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Address: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892. 

Meeting Format: Virtual Meeting. 

Contact Person: John Drake Morgan, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Dr., Room 1015A, 

Bethesda, MD 20892, (301) 827–9283, 

morganjod@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: October 10, 2024. 

Victoria E. Townsend, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23874 Filed 10–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Center of Excellence for 

Systems Modeling of Infection and Immunity 

across Biological Scales (U54 Clinical Trial 

Not Allowed). 

Date: November 21–22, 2024. 

Time: 10:00 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G45, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Vanitha Sundaresa Raman, 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G45, Rockville, MD 

20892, 301–761–7949, vanitha.raman@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 10, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–23838 Filed 10–15–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Division of Intramural 

Research Board of Scientific Counselors, 

NIAID. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in section 

552b(c)(6), title 5 U.S.C., as amended for 

the review, discussion, and evaluation 

of individual intramural programs and 

projects conducted by the National 

Institute of Allergy and Infectious 

Diseases, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 


lotter on DSK11XQN23PROD with NOTICES1